In today’s briefing:
- Jinxin Fertility: Shenzhen and Yunnan Acquisitions
- Intuitive Surgical (ISRG US): 1Q22 Review- Procedure Volume Growth Overshadowed by Macro Headwinds
Jinxin Fertility: Shenzhen and Yunnan Acquisitions
- Jinxin announced in recent days that it further increases stake in Shenzhen Hospital, Jiuzhou Hospital and Hewanjia Hospital.
- In this note, we analyze the impact on the company. We think the acquisition is sensible when the market sentiment is weak.
- We also summarize recent industry development and the company’s FY2021 results. We are turning relatively more bearish.
Intuitive Surgical (ISRG US): 1Q22 Review- Procedure Volume Growth Overshadowed by Macro Headwinds
- Intuitive Surgical (ISRG US) Q1 revenue and EPS beat consensus. High-teens procedure volume growth is the brightest spot and management raised full-year 2022 procedure growth guidance to 12–16%.
- After a strong placement in last couple of quarters, Intuitive is seeing some near-term softening of its system placement pipeline in the U.S.
- In near-term, macro headwinds including regional waves of COVID, staffing pressure at hospitals, component and raw material availability, and logistic delays will remain biggest overhang for the company.
Before it’s here, it’s on Smartkarma
